Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director · President, CEO | December 17, 2021 | December 20, 2021 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2025 | January 03, 2025 |
| VERU INC.VERU · Entity 7234 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date December 17, 2021 · Filed December 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 748,949 |
Reported balance
After 2021-12-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-12-17 · Grant · Acquired 411,616 · Balance 748,949 F1: This restricted stock unit award (RSU) vests on March 15, 2022. Each restricted stock unit is equivalent to one share of the Company's common stock. F2: Includes 411,616 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This restricted stock unit award (RSU) vests on March 15, 2022. Each restricted stock unit is equivalent to one share of the Company's common stock.
F2: Includes 411,616 RSUs.
Fortress Biotech, Inc.
Report date January 01, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 61,273 |
Reported balance
After 2025-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-01 · Grant · Acquired 49,383 · Balance 61,273 F1: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2: Total holdings include 58,047 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
F2: Total holdings include 58,047 shares underlying deferred restricted stock units.
VERU INC.
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2036-05-04 | Direct | 104,000 |
Reported balance
After 2026-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 104,000 · Balance 104,000 F1: Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 20:10 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 104,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001042167-26-000039 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2036-05-04 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 16:28 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 4,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001042167-25-000066 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2035-12-05 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:06 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 6,000 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001042167-25-000047 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2035-10-01 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of October 1, 2026, October 1, 2027 and October 1, 2028. Read SEC document |
| May 06, 2025 Filed May 8, 2025 18:56 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 30,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001042167-25-000025 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-06 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000428 · form4-01032025_040107.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,273 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 58,047 shares underlying deferred restricted stock units. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:37 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 70,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001042167-24-000062 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-10-01 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of October 1, 2025, October 1, 2026 and October 1, 2027. Read SEC document |
| August 06, 2024 Filed Aug 7, 2024 19:56 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 20,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001042167-24-000056 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:55 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000915 · tm241755-9_4seq1.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,890 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3 · balance_after: Total holdings include 8,664 shares underlying deferred restricted stock units. Read SEC document |
| October 02, 2023 Filed Nov 17, 2023 22:51 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 80,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001042167-23-000065 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-10-02 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of October 2, 2024, October 2, 2025 and October 2, 2026. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:54 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 10,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001042167-23-000029 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 9, 2024, May 9, 2025 and May 9, 2026. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:09 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 11,976 | $0.84 | $9,999.96 |
DisclosureSEC source: 0001104659-23-021614 · tm236803-3_4seq1.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,379 F1 · balance_after: The total holdings include 50,000 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:27 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001102 · tm231728-8_4seq1.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,403 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon her death or change in control of the Issuer. F2 · balance_after: The total holdings include 50,000 shares underlying deferred restricted stock units. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 13:50 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-128075 · tm2232939-2_4seq1.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,403 F1 · shares: One-third of the shares will vest on each of December 16, 2023, December 16, 2024 and December 16, 2025. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:39 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 90,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001042167-22-000064 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-11-02 F1 · derivative.exercise_date: Options are annual award grants for fiscal 2023 and options for one-third of the shares vest on each of November 2, 2023, November 2, 2024 and November 2, 2025. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 22:08 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 411,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151774 · tm2135922-4_4seq1.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,949 F1 · shares: This restricted stock unit award (RSU) vests on March 15, 2022. Each restricted stock unit is equivalent to one share of the Company's common stock. F2 · balance_after: Includes 411,616 RSUs. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 15:31 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 70,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001042167-21-000079 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-11-03 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of November 3, 2022, November 3, 2023 and November 3, 2024. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:02 UTC | VERU INC. VERU · Entity 7234 | PurchaseCommon Stock | 4,800 | $6.78 | $32,542.08 |
DisclosureSEC source: 0001042167-21-000061 · primary_doc.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · price: The price reported above is the weighted average transaction price. The range of prices for such transactions is $6.77 to $6.78. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2021 Filed May 18, 2021 19:47 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 70,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001042167-21-000040 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: Options granted for appointment to Board of Directors and committees thereof. Options for one-third of the shares vest on each of May 14, 2022, May 14, 2023 and May 14, 2024. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 21:31 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantRestricted Stock Units · Derivative | 110,959 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-020235 · tm208004-1_form4.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,576 Underlying: Common Stock · 110,959 shares Expires 2025-02-12 F1 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Avenue Therapeutics, Inc. The RSUs vest upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:41 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantRestricted Stock Units · Derivative | 135,617 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-029899 · tv523097_form4.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,617 Underlying: Common Stock · 135,617 shares Expires 2024-06-03 F1 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Avenue Therapeutics, Inc. The RSUs vest upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:48 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042962 · tv500470_form4.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,333 F1 · shares: The 250,000 shares of restricted common stock will vest as follows: one-fourth on August 7, 2019, one-fourth on August 7, 2020, one-fourth on August 7, 2021, and one-fourth on August 7, 2022. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 17:19 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001144204-18-034375 · tv496576_form4.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,333 Read SEC document |
| May 02, 2018 Filed May 4, 2018 15:09 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 50,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001042167-18-000047 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-05-02 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 2, 2019, May 2, 2020 and May 2, 2021. Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 10:09 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 4,000 | $5.20 | $20,800.00 |
DisclosureSEC source: 0001144204-17-050793 · v476242_form4.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,333 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 15:43 UTC | VERU INC. FHCO · Entity 7234 | GrantCommon Stock Option · Derivative | 45,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001042167-17-000076 · primary_doc.xml · derivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-08-02 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of August 2, 2018, August 2, 2019 and August 2, 2020. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:42 UTC | VERU INC. FHCO · Entity 7234 | PurchaseCommon Stock, par value $.01 per share | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001042167-17-000037 · primary_doc.xml · nonDerivative · entry 1 Lu Lucy · CIK 0001542419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.